Canada’s strategy to construct a $267 million medical countermeasures laboratory in Winnipeg has been deemed crucial by experts in preempting future pandemics. However, they caution that the facility will encounter significant obstacles related to sustained funding, staffing, and governance in the long term.
The recent announcement by the federal government of a $10.2 million design contract for the facility, scheduled to be operational by 2033 adjacent to Winnipeg’s National Microbiology Laboratory (NML), is a step forward. The laboratory’s goal is to fill a critical void in the early-stage testing of vaccines, therapeutics, and diagnostic tools. Nonetheless, health researchers emphasize that merely having a new building will not suffice without continuous investments in skilled personnel over decades.
Dr. Joanne Liu, a physician and professor at McGill University’s School of Population and Global Health, stresses the importance of having the necessary human resources to establish a world-class center alongside the physical infrastructure. She emphasizes the importance of aligning actions with intentions in the realm of countermeasures.
The facility aims to enhance Canada’s capacity for preclinical trials, including laboratory and animal testing, within the research and development pipeline. This dedicated space would allow scientists to conduct preliminary tests on small batches of potential vaccines before progressing to clinical trials. Currently, due to space limitations, the NML sometimes repurposes lab facilities intended for volatile pathogen research, such as Ebola, for preclinical testing.
Industry and academic partners could potentially utilize the laboratory spaces with appropriate agreements and screenings in place. Enhancing Canada’s capabilities in preclinical research is a logical step, according to experts who have been advocating for it for over a decade.
Ensuring sustained funding during non-crisis periods is critical, as highlighted by McGill’s Liu. She emphasizes the necessity of investing continuously in virus research and countermeasures even when health threats are not at the forefront of public attention. Liu raises concerns about recent staff reductions at the NML impacting the recruitment of top-tier researchers, stressing the need for funding to support research endeavors.
Gary Kobinger, a former NML scientist involved in developing the world’s first successful Ebola vaccine, underscores the importance of long-term stability for the project. He emphasizes the need for ongoing funding to advance products over the coming years following the construction of the facility.
Kobinger also warns of the risks associated with government-run labs, citing past challenges faced during the development of the Ebola vaccine in Canada. Red tape and funding hurdles could hinder the success of the countermeasures lab. He points to the delays encountered by the Biologics Manufacturing Centre in Montreal as a cautionary tale, stressing the need for effective governance within government structures.
The Public Health Agency of Canada defends its funding allocations, highlighting significant investments in the life sciences sector since 2018. The agency emphasizes collaborations with private industry through new initiatives like Health Emergency Readiness Canada. However, Kobinger asserts that success will hinge on effective leadership and avoiding past pitfalls in handling patents and administrative processes.
